1. Academic Validation
  2. A human iPSC-derived sensory neuron platform for high-throughput discovery of neuroprotectants against chemotherapy-induced peripheral neuropathy

A human iPSC-derived sensory neuron platform for high-throughput discovery of neuroprotectants against chemotherapy-induced peripheral neuropathy

  • Cell Rep Med. 2026 May 19;7(5):102787. doi: 10.1016/j.xcrm.2026.102787.
Veselina Petrova 1 Caitlin E Mills 2 Clemens Hug 3 Aysel Cetinkaya-Fisgin 4 Jennifer Splaine 5 Sepideh Fouladzadeh 6 Sara Hakim 1 Rasheen Powell 1 Shannon Zhen 7 Mirra Chung 2 Gary A Bradshaw 3 Tao Deng 8 Ilyas Singec 8 Qing Wang 9 Riki Kawaguchi 9 Harathi Jonnagaddala 10 Lee B Barrett 1 Jennifer A Smith 5 Marian Kalocsay 10 Benjamin M Gyori 11 Ahmet Hoke 4 Peter K Sorger 2 Clifford J Woolf 12
Affiliations

Affiliations

  • 1 F.M. Kirby Neurobiology Center, Program in Neurobiology, Boston Children's Hospital, Boston, MA, USA; Department of Neurobiology, Harvard Medical School, Boston, MA, USA.
  • 2 Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA; Department of Systems Biology, Harvard Medical School, Boston, MA, USA.
  • 3 Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA.
  • 4 Department of Neurology, Neuromuscular Division, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • 5 ICCB-Longwood Screening Facility, Harvard Medical School, 250 Longwood Avenue, Boston, MA, USA.
  • 6 Department of Bioengineering, Northeastern University, Boston, MA, USA.
  • 7 F.M. Kirby Neurobiology Center, Program in Neurobiology, Boston Children's Hospital, Boston, MA, USA.
  • 8 National Center for Advancing Translational Sciences (NCATS), Division of Preclinical Innovation, Stem Cell Translation Laboratory (SCTL), National Institutes of Health (NIH), Rockville, MD, USA.
  • 9 Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, USA.
  • 10 Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • 11 Department of Bioengineering, Northeastern University, Boston, MA, USA; Khoury College of Computer Sciences, Northeastern University, Boston, MA, USA.
  • 12 F.M. Kirby Neurobiology Center, Program in Neurobiology, Boston Children's Hospital, Boston, MA, USA; Department of Neurobiology, Harvard Medical School, Boston, MA, USA. Electronic address: [email protected].
Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of Cancer treatment, yet the lack of predictive human models continues to hinder therapeutic progress. Here, we establish a scalable and reproducible model of paclitaxel-induced axon degeneration and neurotoxicity in human iPSC-derived sensory neurons, suitable for high-throughput identification of neuroprotective compounds. Using this platform, we screen a library of 192 kinase inhibitors and identify 19 hits that commonly inhibit three STE20 kinases-MAP4K4, MINK1, and TNIK. Genetic knockdown studies reveal that multi-kinase inhibition of these kinases is required for neuroprotection against paclitaxel. Consistently, selective pharmacological inhibition of the identified STE20 kinases rescues paclitaxel-induced axon degeneration in iPSC-derived sensory neurons and primary human dorsal root ganglia (DRG) and preserves intraepidermal nerve fiber density in a mouse model of CIPN. Together, these findings establish a translational human sensory neuron platform that enables target validation and drug discovery for CIPN.

Keywords

STE20 kinases; axon degeneration; chemotherapy-induced peripheral neuropathy; high-throughput screening; iPSC-derived sensory neurons; neuroprotective small molecules.

Figures
Products